What drove the significant increase in net sales for Abbott Laboratories in Q1 2011?

The primary drivers for the 17.4% increase in net sales to $9.04 billion were the acquisitions of Solvay Pharmaceuticals in February 2010 and Piramal Healthcare's Healthcare Solutions business in September 2010. These acquisitions significantly expanded Abbott's product portfolio and global market presence, particularly in established and proprietary pharmaceutical products.

Why did net earnings decrease in Q1 2011 despite strong sales growth?

Net earnings declined by 13.9% to $863.8 million primarily due to increased operating expenses. Research and development expenses rose by 27.4% due to pipeline investment and integration of acquired R&D. Selling, general, and administrative expenses increased by 31.8%, reflecting acquisition integration costs, higher litigation provisions, and healthcare reform fees. Additionally, a $137 million charge was recorded related to a change in accounting principle for foreign subsidiary consolidation.

What is the status of Abbott's major legal proceedings, particularly the Humira patent dispute?

The Federal Circuit reversed a district court's judgment against Abbott in its Humira patent dispute with NYU and Centocor, finding Centocor's patent invalid. While Centocor has petitioned for a rehearing, Abbott is confident in its position, and no reserves have been recorded for this case. Other legal matters related to Norvir, stents, and fenofibrate products have been settled or resolved favorably for Abbott and are no longer considered material.

How did the change in accounting for foreign subsidiary consolidation impact the financial statements?

Effective January 1, 2011, Abbott eliminated a one-month reporting lag for foreign subsidiaries. This change, treated as a change in accounting principle, resulted in a $137 million charge to 'Other (income) expense, net' in the first quarter of 2011 to recognize cumulative immaterial impacts from prior periods. While not material enough to revise prior periods, it affected the current quarter's earnings.

ABT 10-Q Quarterly Report Q1 FY2011 — Revenue, Net Income, EPS

Summary

Abbott Laboratories (ABT) reported its first-quarter 2011 results, showing a significant increase in net sales to $9.04 billion, up 17.4% from $7.70 billion in the prior year. This growth was primarily driven by the strategic acquisitions of Solvay Pharmaceuticals and Piramal Healthcare, which bolstered the Established Pharmaceutical Products and Proprietary Pharmaceutical Products segments, as well as strong performance in international markets. Despite the top-line growth, net earnings decreased to $863.8 million from $1,003.0 million in the prior year, resulting in a diluted EPS of $0.55 compared to $0.64. This decrease in profitability was influenced by increased operating costs, including higher research and development, selling, general and administrative expenses, and a notable charge related to a change in accounting principle for foreign subsidiary consolidation.

Financial Highlights

53 data points

Beta

Revenue

$9.04B

0.6% Gross Margin

Net Income

$863.80M

0.1% Net Margin

EPS (Diluted)

$0.55

Total Assets

$61.65B

Cash & Equivalents

$2.74B

Free Cash Flow

$1.62B

Financial Statements

Beta

Revenue	$9.04B
Cost of Revenue	$3.86B
Gross Profit	$5.18B
SG&A Expenses	$2.85B
Operating Expenses	$7.74B
Operating Income	$1.30B
Interest Expense	$145.59M
Net Income	$863.80M
EPS (Basic)	$0.56
EPS (Diluted)	$0.55
Shares Outstanding (Basic)	1.55B
Shares Outstanding (Diluted)	1.56B

Key Highlights

1Net sales surged by 17.4% year-over-year to $9.04 billion, largely due to significant acquisitions in the pharmaceutical sector.
2Acquisitions of Solvay Pharmaceuticals and Piramal Healthcare boosted sales, particularly in the Established Pharmaceutical Products and Proprietary Pharmaceutical Products segments.
3International sales showed robust growth, increasing by 24.3% to $5.52 billion, indicating successful global expansion.
4Despite revenue growth, net earnings declined by 13.9% to $863.8 million, leading to a decrease in diluted EPS from $0.64 to $0.55.
5Research and development expenses increased by 27.4%, reflecting continued investment in pipeline development across various therapeutic areas and medical devices.
6Selling, general, and administrative expenses rose by 31.8%, impacted by acquisition integration costs, increased provisions for litigation, and healthcare reform fees.
7The company successfully resolved several legal disputes, including patent infringements related to Humira, Norvir, and various stent and fenofibrate products.

ABBOTT LABORATORIES Quarterly Report for Q1 Ended Mar 31, 2011

Summary

Financial Highlights

Key Highlights

Frequently Asked Questions